August 31, 2022
Eisai said on August 30 that it has made a Japan submission for an additional injection formulation of its first-in-class antiepileptic med Fycompa (perampanel). Fycompa is a selective, noncompetitive AMPA receptor antagonist that suppresses neuronal hyperexcitation by targeting glutamate activity...read more